Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies

Learn more about:
Related Clinical Trial
A Phase 1, Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell and Indolent B-Cell Lymphomas Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas AMG 319 Lymphoid Malignancy FIH Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies Tandem Auto-Allo Transplant for Lymphoma Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma Long-term Follow-up of Patients Treated With Autologous T Cells Genetically Modified Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies. p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas CD4CAR for CD4+ Leukemia and Lymphoma Pembrolizumab for T/NK-cell lymphomasNK-cell Lymphomas Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma A Study for Patients With Non-Hodgkin’s Lymphomas High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma Allo-HSCT as First-line Consolidation in High-risk PTCL A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study) A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low ( T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas Patients A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL) Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed Peripheral T-cell Lymphomas (PTCL) ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia A Multicenter Clinical Trial of Daratumumab in Combination With Gemcitabine, Dexamethasone and Cisplatin in Patients With Relapsed/Refractory CD38 Positive PTCL-NOS, Angioimmunoblastic T-cell Lymphoma AITL and Other Nodal Lymphomas of T Follicular Helper Cells Origin Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin’s Lymphoma HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma Gemcitabine in NK/T Cell Lymphoma A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma Trial of Endostar Combined With CHOPT for T Cell Lymphoma Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

Brief Title

Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies

Official Title

Efficacy and Safety of Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies:a Single-center, Open, Single-arm Clinical Study.

Brief Summary

      The overall purpose of this study is to explore the safety and therapeutic effect of
      CD30-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of
      Refractory/Relapsed lymphocyte malignancies.

Detailed Description

      Chimeric antigen receptor (CAR)-modified T cells (CAR-T cells) have the capabilities to
      recognize tumor associated antigen and kill tumor cells specifically. CD30 is originally
      described as a marker of Hodgkin's and R-S cells in Hodgkin's lymphoma. CD30 antibody has
      been applied to treat lymphocyte derived malignancies. To explore the potency of CD30 in
      CAR-T therapy, this trial is designed and conducted to test the safety and efficacy of
      CD30-targeted CAR-T in Refractory/Relapsed lymphocyte malignancies.

Study Phase

Phase 1

Study Type


Primary Outcome

Number of participants with adverse events

Secondary Outcome

 One-month remission rate


Adult T-Cell Lymphoma/Leukaemia


Anti-CD30 CAR T cells

Study Arms / Comparison Groups

 Anti-CD30 CAR T cells
Description:  Patients receive CD30 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity. Autologous 3th generation anti-CD30 CAR T cells.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

July 3, 2019

Completion Date

January 1, 2023

Primary Completion Date

July 1, 2022

Eligibility Criteria

        Inclusion Criteria:

          1. Patient or his or her legal guardian voluntarily participates in and signs an informed
             consent form.

          2. Male or female patients aged 18 to 70 years (including 18 and 70 years old).

          3. Pathological and histological examination confirmed CD30+ lymphocyte malignancies, and
             patients currently have no effective treatment options, such as chemotherapy or
             recurrence after hematopoietic stem cell transplantation; or patients voluntarily
             choose Anti-CD30 CAR-T as rescue treatment.

          4. CD30+ lymphocyte malignancies:

               1. Adult T-cell leukemia/lymphoma

               2. Anaplastic large cell lymphoma (ALCL);

               3. Angioimmunoblastic T-cell Lymphoma (AITL);

               4. NK/T-cell lymphoma;

               5. Peripheral T-cell lymphoma (PTCL);

               6. Hodgkin lymphoma;

          5. Subjects:

               1. There are still residual lesions after major treatment, and they are not suitable
                  for HSCT (auto/allo-HSCT);

               2. Recurrence occurs after CR1, and HSCT (auto/allo-HSCT) is not selected or
                  suitable because of self-willingness;

               3. After hematopoietic stem cell transplantation or cellular immunotherapy, the
                  patient suffered relapse or did not remission.

          6. Having a measurable or evaluable lesion.

          7. Patient's main organs function well:

               1. Liver function: ALT/AST < 3 times the upper limit of normal (ULN) and

               2. total bilirubin≤34.2μmol/L

               3. Renal function: Creatinine < 220μmol/L.

               4. Pulmonary function: Indoor oxygen saturation≥95%.

               5. Cardiac Function: Left ventricular ejection fraction (LVEF) ≥40%.

          8. The patients did not receive any anticancer treatments such as chemotherapy,
             radiotherapy and immunotherapy (such as immunosuppressive drugs) within 4 weeks before
             admission, and the toxicity related to previous treatments had returned to < 1 level
             at admission (except for low toxicity such as alopecia).

          9. The patient's peripheral superficial venous blood flow smoothly, which can meet the
             needs of intravenous drip.

         10. Patient ECOG score≤2, Estimated survival time≥3 months.

        Exclusion Criteria:

          1. Women who are pregnant (urine/blood pregnancy test positive) or lactating.

          2. Male or female with a conception plan in the past 1 years.

          3. Patients cannot guarantee effective contraception (condom or contraceptives, etc.)
             within 1 years after enrollment.

          4. Uncontrolled infectious disease within 4 weeks prior to enrollment.

          5. Active hepatitis B/C virus.

          6. HIV infected patients.

          7. Suffering from a serious autoimmune disease or immunodeficiency disease.

          8. The patient is allergic and is allergic to macromolecular biopharmaceuticals such as
             antibodies or cytokines.

          9. The patient participated in other clinical trials within 6 weeks prior to enrollment.

         10. Systemic use of hormones within 4 weeks prior to enrollment (except for patients with
             inhaled corticosteroids).

         11. Have a history of epilepsy or other central nervous system diseases.

         12. Having drug abuse/addiction.

         13. According to the researcher's judgment, the patient has other unsuitable grouping




18 Years - 70 Years

Accepts Healthy Volunteers



Heng Mei, M.D. Ph.D, 86-13986183871, [email protected]

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party

Principal Investigator

Study Sponsor

Wuhan Union Hospital, China


 Wuhan Bio-Raid Biotechnology Co, Ltd. China

Study Sponsor

Heng Mei, M.D. Ph.D, Principal Investigator, Wuhan Union Hospital, China

Verification Date

August 2019